Antiplatelet therapy early after bioprosthetic aortic valve replacement is unnecessary in patients without thromboembolic risk factors | Zendy

Martin Brueck | Zendy; Wilfried Kramer | Zendy; Paul Vogt | Zendy; Nicole Steinert | Zendy; P. Roth | Zendy; G. Görlach | Zendy; Markus Schönburg | Zendy; Martin Heidt | Zendy

Open Access

Antiplatelet therapy early after bioprosthetic aortic valve replacement is unnecessary in patients without thromboembolic risk factors

Author(s) -

Martin Brueck,

Wilfried Kramer,

Paul Vogt,

Nicole Steinert,

P. Roth,

G. Görlach,

Markus Schönburg,

Martin Heidt

Publication year - 2007

Publication title -

european journal of cardio-thoracic surgery

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.303

H-Index - 133

eISSN - 1873-734X

pISSN - 1010-7940

DOI - 10.1016/j.ejcts.2007.03.031

Subject(s) - medicine , aspirin , antithrombotic , warfarin , surgery , aortic valve replacement , cardiology , sinus rhythm , atrial fibrillation , stenosis

The use of antithrombotic therapy during the postoperative period after biological aortic valve replacement (AVR) in patients without thromboembolic risk factors remains controversial. Treatment with warfarin is recommended for the first 3 months after biological AVR. The use of antiplatelet therapy - mainly aspirin (ASA) - is suggested as an alternative treatment but its efficacy is still unsettled. Due to the increased risk of bleeding complications even no use of any antithrombotic or antiplatelet therapy was advocated. Given this ongoing dispute, the aim of this retrospective double-institutional study was to evaluate the necessity of antiplatelet treatment by ASA with no postoperative antiplatelet therapy in terms of survival, major bleedings and cerebral thromboembolism of patients undergoing biological AVR without thromboembolic risk factors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research